Pleiotropic Effect of Metoprolol: Different From other B-blockers

The clinical practice guidelines recommend the early use of endovenous B-blockers in patients undergoing acute myocardial MI, taking for granted that all B-blockers have a similar class effect. 

Beta Bloqueantes

This experimental study might show metoprolol has other benefits that could make it superior to the rest of the B-blocker family. 

Using an animal model with 45-minute ongoing ischemia, metoprolol, atenolol, or propranolol was administered at min 35.

Ten minutes after administering one of the three B-blockers (blindly and in a randomized fashion) reperfusion was carried out, and after 24 hours, the pathological anatomy test was carried out. 

Out of all B blockers tested, only metoprolol reduced the damage caused by injury/reperfusion and MI size compared against atenolol and propranolol (p<0.001).


Read also: N95 and Surgical Face Mask Sterilization Is Feasible.


Neutrophil infiltration resulted significantly lower only with metoprolol. This was observed both in the MI injury/reperfusion model and in inflammation models such as thioglycolate-induced peritonitis, or lipopolysaccharide-induced acute lung injury. 

Cell migration studies confirmed this particular ability of metoprolol to attenuate neutrophil dynamics. 

There was also a change in B1 receptor conformational changes when bound to metoprolol (different from the other two β-blockers).

Conclusion

Metoprolol can limit neutrophil action, reducing inflammation and resulting in a smaller infarct size, something not observed with propranolol or atenolol. 

This differential effect of metoprolol compared against other drugs of the same family might be due to a different conformation of B1 receptor when bound to it. If more studies confirm this effect, metoprolol might become the B-blocker of choice for treating patients undergoing acute myocardial infarction. 

ehaa733free

Original Title: Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation.

Reference: Agustín Clemente-Moragón et al. European Heart Journal (2020) 41, 4425–4440. doi:10.1093/eurheartj/ehaa733.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....